MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
RadNet Interest Expense 2011-2026 | RDNT
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense RadNet
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24.9 M | 6.35 M | -1.83 M | -1.44 M | -120 K | -1.28 M | 181 K | 258 K | 21 K | 34 K | 60 K | 86 K | 245 K | 381 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 24.9 M | -1.83 M | 1.99 M |
Quarterly Interest Expense RadNet
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.04 M | 7.76 M | - | 5.41 M | 7.9 M | - | 4.08 M | -40 K | -1.43 M | - | -1.4 M | 7 K | -165 K | - | 167 K | -1.66 M | -206 K | - | 139 K | 115 K | -6 K | - | -2 K | -1.27 M | - | - | -7 K | -5 K | -1 K | - | -4 K | -7 K | 247 K | - | -174 K | -4 K | -2 K | - | -8 K | -413 K | 3 K | - | -6 K | 4 K | -2 K | - | -4 K | -150 K | 2 K | - | 1.36 M | 1.34 M | 1.15 M | - | 1.51 M | 689 K | 1.87 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 9.04 M | -1.66 M | 853 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Trinity Biotech plc
TRIB
|
6.75 M | $ 0.73 | -1.86 % | $ 61.9 M |  Irlanda |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 29.0 | -3.07 % | $ 316 M |  China |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
-10.1 M | $ 1.14 | -2.16 % | $ 1.45 M | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
Celcuity
CELC
|
2.11 M | $ 104.95 | -1.72 % | $ 4.14 B | USA |
 |
Co-Diagnostics
CODX
|
106 K | - | - | $ 79.8 M | USA |
 |
Danaher Corporation
DHR
|
-56 M | $ 210.56 | -0.33 % | $ 154 B | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 29.41 | -6.17 % | $ 817 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
Quest Diagnostics Incorporated
DGX
|
30 M | $ 202.21 | -0.11 % | $ 22.4 B | USA |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
DexCom
DXCM
|
177 M | $ 73.08 | 1.11 % | $ 28.5 B | USA |
 |
DarioHealth Corp.
DRIO
|
-31 K | $ 11.75 | 2.8 % | $ 333 M | Israel |
 |
CareDx, Inc
CDNA
|
1.34 M | $ 18.83 | -5.23 % | $ 1.01 B | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Illumina
ILMN
|
-292 M | $ 117.53 | -2.06 % | $ 18.7 B | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 23.18 | -0.39 % | $ 701 M | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | $ 103.45 | 0.15 % | $ 19.5 B | USA |
 |
Lantheus Holdings
LNTH
|
37.2 M | $ 74.31 | 1.54 % | $ 5.14 B | USA |
 |
Guardant Health
GH
|
-10.5 M | $ 103.36 | -2.84 % | $ 13 B | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 99.61 | 1.22 % | $ 8.22 B | Irlanda |
 |
Interpace Biosciences
IDXG
|
-394 K | $ 1.85 | 2.78 % | $ 8.12 M | USA |
 |
QIAGEN N.V.
QGEN
|
-739 K | - | - | $ 10.6 B |  Niderland |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 169.68 | 3.11 % | $ 8.41 B | USA |
 |
IDEXX Laboratories
IDXX
|
29.8 M | $ 635.6 | 0.77 % | $ 52.4 B | USA |
 |
IQVIA Holdings
IQV
|
729 M | $ 166.19 | -1.87 % | $ 28.6 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 31.19 | 0.73 % | $ 20 B | Niderland |
|
Biodesix
BDSX
|
8.26 M | $ 13.26 | 4.0 % | $ 1.72 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
208 M | $ 283.38 | 0.32 % | $ 23.8 B | USA |
 |
Biomerica
BMRA
|
367 | $ 2.17 | -2.25 % | $ 4.98 M | USA |
 |
Bioventus
BVS
|
1.29 M | $ 8.57 | -0.06 % | $ 537 M | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 452.99 | 1.47 % | $ 13.1 B | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
National Research Corporation
NRC
|
862 K | $ 13.65 | 9.64 % | $ 335 M | USA |
 |
Mettler-Toledo International
MTD
|
68.5 M | $ 1 378.44 | 0.14 % | $ 28.4 B |  Schweiz |